<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1500">
  <stage>Registered</stage>
  <submitdate>13/03/2007</submitdate>
  <approvaldate>13/03/2007</approvaldate>
  <nctid>NCT00448058</nctid>
  <trial_identification>
    <studytitle>A Study Of New Medicine (GSK 372475) For The Treatment Of Depression</studytitle>
    <scientifictitle>A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/Day to 2.0 mg/Day) or Extended Release Venlafaxine XR (150 mg/Day to 225 mg/Day) Compared to Placebo in Adult s</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SND 103285</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depressive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GSK372475
Treatment: drugs - venlafaxine
Treatment: drugs - placebo

Experimental: GSK372475 - flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day

Active Comparator: Venlafaxine - Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day

Placebo Comparator: placebo - 


Treatment: drugs: GSK372475
daily administration during the 10-week treatment phase

Treatment: drugs: venlafaxine
daily administration during the 10-week treatment phase

Treatment: drugs: placebo
daily administration during the 10-week treatment phase

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from randomization to the end of the Treatment Phase (Week 10) on a depression rating scale.</outcome>
      <timepoint>Randomisation (week 0) And end of the treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Endpoints related to response &amp; remission on depression rating scales during time of treatment exposureChange during treatment &amp; at endpoint-week 10:in Clinical Global Impression scale; in motivation, energy, &amp; sexual functioning on patient-rated scales</outcome>
      <timepoint>Randomisation (week 0) and at weeks 1,2,4,6,8 and week 10 (end of treatment phase)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Major depressive episode (MDE) associated with Major Depressive Disorder (DSM-IV-TR
             criteria)

          -  Duration of current episode is at least 12 weeks duration and less than 2 years

          -  Symptoms of decreased energy, pleasure, and interest

          -  Female subjects who agree to use acceptable methods of birth control throughout the
             study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>64</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Current diagnosis of Panic Disorder, or symptoms of generalized anxiety or panic
             attacks that could interfere with their ability to complete the trial

          -  Symptoms of MDE better accounted for by another diagnosis

          -  Diagnosis of Bipolar, schizophrenia, other psychotic disorder(s), borderline or
             antisocial personality disorder, or dementia.

          -  Started psychotherapy within 3 months prior to the Screening

          -  Received electroconvulsive therapy or transcranial magnetic stimulation within 6
             months prior to screening

          -  Received psychoactive drugs within 4 weeks of randomization

          -  Positive urine drug screen or positive blood alcohol

          -  Suicidal risk or has had any previous suicide attempt, a family history of suicide
             attempt

          -  Positive pregnancy test

          -  History of seizure disorder, myocardial infarction (&lt; 1yr), or unstable medical
             condition

          -  Failed to respond to an adequate course of pharmacotherapy of at least 2 different
             antidepressants</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>396</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>GSK Investigational Site - Auchenflower</hospital>
    <hospital>GSK Investigational Site - Kippa Ring</hospital>
    <hospital>GSK Investigational Site - Epping</hospital>
    <hospital>GSK Investigational Site - Heidelberg West</hospital>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Li√®ge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mont-Godinne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Burgas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Voru</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Arcachon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg-Vorpommern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tirupati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Skorzewo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Michalovce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Observatory ,Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Somerset West</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Vereeniging</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the
      treatment of outpatient subjects with Major Depressive Disorder (MDD)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00448058</trialwebsite>
    <publication>Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol. 2012 May;26(5):653-62. doi: 10.1177/0269881111424931. Epub 2011 Nov 2.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>